Windlas Biotech Limited has informed the Exchange about Outcome of Nomination and Remuneration Committee Meeting
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Windlas Biotech's Nomination and Remuneration Committee has amended the 'Windlas Plan 2025' stock unit (ESOP) scheme to provide clearer disclosures to stock exchanges. The amendment sets a new cap of 2,09,590 units per eligible employee per grant per year, while keeping the shareholder-approved aggregate limit of 3,15,000 units per employee unchanged. If any single grant equals or exceeds 1% of the company's issued capital, additional compliance steps under Sub-clause 3.3 will apply. The company clarified that the change is purely clarificatory and does not increase or alter any limits already approved by shareholders. The updated plan has been uploaded to the company's website.
No material impact for shareholders — the amendment is a technical, disclosure-related tweak that preserves existing ESOP limits, suggesting a disciplined approach to employee stock incentives without diluting shareholder-approved boundaries.